NCT02916771View on ClinicalTrials.gov

Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

PHASE2CompletedINTERVENTIONAL

Enrollment

61

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

January 8, 2025

Study Completion Date

January 8, 2025

Conditions

Smoldering Multiple Myeloma

Interventions

DRUG

Ixazomib

Oral, proteasome inhibitor

DRUG

Lenalidomide

Oral, immunomodulatory agent

DRUG

Dexamethasone

Oral, steroid

Trial Locations (1)

02115

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (2)

All Listed Sponsors

collaborator

Celgene

INDUSTRY

collaborator

Takeda

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER